The current health system places increasing pressure on physicians and their practices to find new and innovative ways to maximize reimbursement through the implementation of programs and workflows that ensure the delivery of higher quality care—all while the ever-increasing needs of the patient population are placing a greater demand on physician time.
Revisiting Rounds: Lessons from the General Medicine Ward
Lessons from the general medicine ward
Fatal Choices: Mixing Risk with Medicine
Mixing risk with medicine
The Law of Unintended Consequences Rears Its Head
A program to improve drug safety has increased drug prices for patients with gout and FMF
Letters to the Editor: In Memoriam
One more prescribing rule [See “Rheuminations,” September 2009, p. 6], honored mainly in the breach, in our overspending climate: don’t prescribe an expensive brand when generics are as good or better, especially Nexium (which I have never prescribed) versus omeprazole, Lipitor versus simvastatin (which now costs the VA three cents a pill), and—for rheumatologists who are writing 80% Uloric—allopurinol except for the 10% who might need Uloric.
REMS Required
How will this FDA drug safety program affect rheumatology offices?
Pisetsky’s Rules vs. the Peltzman Effect
Pondering drug safety
Drug Risk Versus Benefit
Perceptions from the FDA, physicians, and patients
Drug Updates
Information on safety, labeling changes, and pharmaceutical research
Safety First
Phase 1 clinical trials present recruitment challenges for rheumatology researchers